Giredestrant combined with palbociclib is in clinical development for previously untreated oestrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer. Breast cancer arises from the tissues of the breast and most commonly originates in the cells that line the milk ducts. This kind of ER-positive cancer has receptor cells for the hormone oestrogen, meaning the cancer often responds to treatment with endocrine therapy. Other therapies for this patient population are administered via intravenous injection which can be uncomfortable for the patient and costly. In addition, prolonged treatment and risk of relapse can represent significant challenges for patients; therefore, a need remains for more effective and acceptable treatment options.
Giredestrant with palbociclib for previously untreated advanced or metastatic breast cancer
Giredestrant combined with palbociclib is in clinical development for previously untreated oestrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer. Breast cancer arises from the tissues of the breast and most commonly originates in the cells that line the milk ducts.